- Home
- OMH vs PHGE Comparison
OMH vs PHGE Comparison
Compare OMH & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- PHGE
- Stock Information
- Founded
- OMH 2015
- PHGE 2015
- Country
- OMH Singapore
- PHGE Israel
- Employees
- OMH N/A
- PHGE N/A
- Industry
- OMH Real Estate
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- PHGE Health Care
- Exchange
- OMH Nasdaq
- PHGE Nasdaq
- Market Cap
- OMH 13.6M
- PHGE 11.0M
- IPO Year
- OMH 2023
- PHGE N/A
- Fundamental
- Price
- OMH $1.47
- PHGE $0.41
- Analyst Decision
- OMH Hold
- PHGE Strong Buy
- Analyst Count
- OMH 1
- PHGE 1
- Target Price
- OMH N/A
- PHGE $15.00
- AVG Volume (30 Days)
- OMH 179.3K
- PHGE 288.5K
- Earning Date
- OMH 07-18-2025
- PHGE 08-13-2025
- Dividend Yield
- OMH N/A
- PHGE N/A
- EPS Growth
- OMH N/A
- PHGE N/A
- EPS
- OMH N/A
- PHGE N/A
- Revenue
- OMH $7,976,578.00
- PHGE N/A
- Revenue This Year
- OMH $28.40
- PHGE N/A
- Revenue Next Year
- OMH $23.07
- PHGE N/A
- P/E Ratio
- OMH N/A
- PHGE N/A
- Revenue Growth
- OMH 117.53
- PHGE N/A
- 52 Week Low
- OMH $0.59
- PHGE $0.34
- 52 Week High
- OMH $6.20
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- OMH 45.64
- PHGE 37.32
- Support Level
- OMH $1.32
- PHGE $0.42
- Resistance Level
- OMH $1.60
- PHGE $0.47
- Average True Range (ATR)
- OMH 0.10
- PHGE 0.04
- MACD
- OMH 0.03
- PHGE -0.00
- Stochastic Oscillator
- OMH 53.07
- PHGE 7.17
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).